Why so many women are being diagnosed with ADHD in Perimenopause
Something is happening in GP surgeries across the UK, in menopause clinics in Australia, and in women's health practices globally. The clinical world is only beginning to catch up with the women themselves.
A woman arrives describing brain fog, emotional dysregulation, an inexplicable collapse in her ability to function. The thyroid is fine. The HRT is helping, but not enough. The antidepressants were a dead end. And then, in her 40s or sometimes her 50s, she is diagnosed with ADHD for the first time.
If this sounds familiar, either from a clinical perspective or a personal one, it is because it is happening everywhere. A 2025 survey of 1,500 women found that 94% of those with ADHD reported their symptoms worsened during perimenopause and menopause. A 2026 Danish cohort study tracking 2.8 million children over 25 years found the sex gap in ADHD diagnosis has narrowed substantially, with the steepest increase in rates among girls and women.
This is not a social media trend. It is the visible surface of a much older story. One that starts in the 1970s, runs through decades of research bias, and arrives in the perimenopause clinic today.
The research left women out
ADHD as a clinical category was built almost entirely on studies of hyperactive boys. The diagnostic criteria that emerged reflected a male presentation: externally visible, disruptive, hyperactive. Girls with ADHD, who more commonly present with inattention, internal restlessness, and emotional dysregulation rather than visible hyperactivity, were systematically absent from the evidence base that shaped how an entire generation of clinicians were trained to see the condition.
The result was predictable. Girls who could not sit still got diagnosed. Girls who could not focus but sat quietly and tried harder did not. They developed compensatory strategies instead: perfectionism, overachievement, exhausting cognitive effort to appear functional. A 2020 expert consensus statement in BMC Psychiatry, drawing on 423 citations, documented this pattern comprehensively. A 2021 annual research review of ADHD in girls and women confirmed it with 273 citations.
A 2024 national study of 16,458 individuals in Wales found that females with ADHD were more likely to receive a diagnosis of anxiety or depression, and to be prescribed antidepressants, before anyone considered a neurodevelopmental explanation. Females required significantly more prominent externalising behaviours to reach the diagnostic threshold that males cleared with less severity.
The girls who adapted by masking, overachieving, and building sophisticated compensatory strategies became invisible to clinicians. And they stayed invisible, in many cases, until perimenopause.
Why perimenopause is the unmasking moment
The connection between oestrogen and ADHD is biological and well-established. Oestrogen stimulates dopamine synthesis in the brain, reduces its reuptake and degradation, and modulates the prefrontal cortex and basal ganglia: the brain structures most implicated in ADHD. For women with ADHD, oestrogen has been doing quiet neurological compensatory work their entire lives.
When oestrogen declines and fluctuates during perimenopause, that compensation collapses. Core ADHD symptoms worsen. Emotional regulation becomes harder. Medication that previously worked may become less effective. And the compensatory strategies these women have built over decades, the systems, the routines, the elaborate scaffolding, stop holding.
A 2025 study in the Journal of Attention Disorders found that more than half of women with ADHD experience debilitating perimenopausal symptoms, compared to one-third of women without ADHD. The differences were most pronounced at ages 35 to 39, suggesting the hormonal impact on ADHD begins nearly a decade earlier than the average perimenopausal timeline.
For women who were already diagnosed, this is a crisis of management. For the women who were never diagnosed, and there are very many of them, perimenopause is often the moment the mask finally comes off entirely.
Why now specifically
If the biology has always been there and the diagnostic gap has always existed, why are we seeing so many diagnoses now? Three things have converged.
Clinician awareness has improved. The Lancet Psychiatry published a significant personal view in 2024 asking directly why females are less likely to be diagnosed with ADHD in childhood. The conversation is now happening in professional literature, not just patient communities. A 2026 critical review in the Journal of Clinical Medicine synthesised the evidence on sex bias in ADHD diagnosis and called explicitly for more sex-sensitive diagnostic frameworks.
The population data is catching up. A UK primary care study of 7.6 million individuals found that ADHD diagnoses and prescriptions increased most proportionally among adults over the study period, with women driving a significant share of that increase. In Australia, where females have historically been excluded from research in similar ways, the same pattern is emerging.
And women are naming it themselves. The combination of greater public awareness, lived experience communities, and access to clinical information means that women who spent their lives being told they were anxious, disorganised, or simply not trying hard enough are encountering frameworks that reframe their entire history. For many, perimenopause is both the crisis that forces the reckoning and the moment they finally have language for what they have been experiencing.
What the diagnosis does and does not solve
A late ADHD diagnosis in perimenopause is, for most women who receive one, a profound relief. It reframes a lifetime. It explains why certain things were always harder than they should have been. It opens access to medication and clinical support that can genuinely help.
But a diagnosis is not a solution. It is an explanation.
Women coming through this process have spent forty or fifty years building their lives around a brain they did not understand. The compensatory systems that kept everything running have collapsed under the hormonal load. What they need alongside medical management is practical: new strategies, new structures, a renegotiated relationship with how their brain actually works now rather than how it worked at 38.
That is not something HRT or stimulant medication provides, even when both are working well. Clinical care manages the neurobiological environment. Practical support builds the infrastructure for living in it. For late-diagnosed women navigating perimenopause simultaneously, both matter. And they work best when the professionals delivering them are working in the same direction.
What this means if you work with these women
If you are a women's health practitioner, you are almost certainly already seeing this patient. She may not yet have a diagnosis. She may have one that is very recent and completely disorienting. She may be on HRT, on medication, or on nothing, and still struggling with a presentation that does not fully resolve with what you have available in a clinical consultation.
The questions she is asking, what do I actually do differently, how do I make this work in practice, why is everything still so hard even though I am doing everything right, are not questions that fall within clinical scope. But they have answers.
If you work with women in midlife and you are seeing this presentation, I have put together a free clinical reference covering the biology, the diagnostic challenge, the limits of pharmacological intervention, and what a structured referral pathway looks like in practice. It is peer-reviewed, evidence-informed, and written for practitioners.
A 20-minute Clinician Discovery Call is the starting point for building something more structured.
And if you are reading this as a woman who recognises herself in any of it: the diagnosis that came too late, the systems that stopped working, the perimenopause that finally made everything visible. The client discovery session is where we start.
Angella Newell is an ADDCA-trained ADHD coach, founder of Winning with ADHD, and a late-diagnosed adult. She works virtually with late-diagnosed adults across the UK, Australia, Portugal, and globally. ADDCA is accredited by both the ICF and PAAC.